Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Death
This study has been completed.
Information provided by (Responsible Party):
First received: May 24, 2011
Last updated: November 13, 2012
Last verified: November 2012
The purpose of this study is to estimate the risk of myocardial infarction (MI)/coronary death associated with use of monotherapy low dose ASA (single antiplatelet) as well as concomitant use of monotherapy low dose ASA and proton pump inhibitors (PPIs) in first- time users of low dose ASA for secondary prevention using a UK primary care database.
Nonfatal Myocardial Infarction
||Observational Model: Cohort
Time Perspective: Retrospective
||Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death - Nested Case Control Analyses in a Cohort of First-time Users of Low Dose ASA for Secondary Prevention of Cerebrovascular and Cardiovascular Outcomes.
Primary Outcome Measures:
- Nonfatal MI or coronary death [ Time Frame: Up to eight years from entry into study cohort ] [ Designated as safety issue: Yes ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||December 2011 (Final data collection date for primary outcome measure)
Cases with nonfatal MI or coronary death
Age, sex, and calendar-year matched controls sampled from the original study cohort to be a round number of at least four times the number of cases
Number of Anticipated Subjects: In case-control analysis 5.000-10.000
|Ages Eligible for Study:
||50 Years to 84 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
All patients aged 50 to 84 years with a first ever prescription of low-dose ASA (defined as 75-300 mg/day) for the secondary prevention of cardiovascular or cerebrovascular events (defined as any previous ischemic cerebrovascular event or ischemic heart disease) from 1 January 2000 to 31 December 2007.
- As above (study population description).
- All individuals aged 50-84 years with at least two year of enrolment with the primary care physician (PCP) and a computerized prescription history of at least one year before the start of the study.
- Recorded diagnosis of cancer prior to study start.
- Alcohol abuse or alcohol-related disease prior to study start.
- Patients aged ≥ 70 years with a follow-up longer than one year if having fewer than two recorded consultations with a primary care physician (PCP) during their entire follow-up (proxy for incomplete and invalid data recording) which for some individuals will be close to 8 years.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01360047
|Madrid, Spain |
||Luis A Garcia Rodriguez
||CEIFE (Centro Español de Investigación Farmacoepidemiológica)
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||May 24, 2011
||November 13, 2012
||Europe: BfArM (Bundesinstitut fur Arznemittel und Medizineprodukte)
Keywords provided by AstraZeneca:
low dose aspirin
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 21, 2015
Proton Pump Inhibitors
Anti-Inflammatory Agents, Non-Steroidal
Central Nervous System Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Physiological Effects of Drugs
Platelet Aggregation Inhibitors